X4制药(XFOR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

XFOR X4制药

盘前交易 08-27 05:58:48 EDT

4.17

+0.01

+0.24%

盘前4.17

+0.000.00%

04:00 EDT

最高4.23	最低4.08	成交量70.71万
今开4.16	昨收4.16	日振幅3.73%
总市值4.13亿	流通市值2.60亿	总股本9,915万
成交额293.21万	换手率1.13%	流通股本6,235万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"XFOR","market":"US","secType":"STK","nameCN":"X4制药","latestPrice":4.17,"timestamp":1787774400000,"preClose":4.16,"halted":0,"volume":707142,"hourTrading":{"tag":"盘前","latestPrice":4.17,"preClose":4.17,"latestTime":"04:00 EDT","volume":30,"amount":125.1,"timestamp":1787817612367,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0024038461538461024,"floatShares":62354300,"shares":99146700,"eps":-1.2404,"marketStatus":"盘前交易","change":0.01,"latestTime":"08-27 05:58:48 EDT","open":4.16,"high":4.23,"low":4.075,"amount":2932053.988848,"amplitude":0.03726,"askPrice":4.59,"askSize":100,"bidPrice":3.65,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.2404,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787837400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1510808400000,"exchange":"NASDAQ","adjPreClose":4.17,"preHourTrading":{"tag":"盘前","latestPrice":4.17,"preClose":4.17,"latestTime":"04:00 EDT","volume":30,"amount":125.1,"timestamp":1787817612367,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.11,"preClose":4.17,"latestTime":"19:30 EDT","volume":1109,"amount":4615.26,"timestamp":1787787003625,"change":-0.06,"changeRate":-0.014388,"amplitude":0.014388},"volumeRatio":1.2290508034023337,"impliedVol":3.4307,"impliedVolPercentile":0.9722},"requestUrl":"/m/hq/s/XFOR/tweets","defaultTab":"tweets","newsList":[{"id":"1168636498","title":"Leerink Partners首予X4制药“跑赢大盘”评级，目标价12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168636498","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168636498?lang=zh_cn&edition=full","pubTime":"2026-06-02 18:15","pubTimestamp":1780395314,"startTime":"0","endTime":"0","summary":"Leerink Partners近日对X4制药公司启动了首次覆盖研究，并给予其“跑赢大盘”的积极评级。该机构同时设定了12美元的目标股价，为市场提供了明确的估值参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108962854","title":"X4制药拟通过SEC备案发行3亿美元混合证券组合","url":"https://stock-news.laohu8.com/highlight/detail?id=1108962854","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108962854?lang=zh_cn&edition=full","pubTime":"2026-05-07 04:13","pubTimestamp":1778098416,"startTime":"0","endTime":"0","summary":"生物制药企业X4 Pharmaceuticals Inc近日向美国证券交易委员会提交文件，宣布可能通过混合证券发行募集最高3亿美元资金。此次融资方案涵盖普通股、优先股、债务证券、认股权证及/或组合单元等多种金融工具。\n根据公开披露的备案信息，该公司保留了根据市场条件灵活选择发行证券类型和条款的权利。这种混合融资架构允许企业根据实际需求优化资本结构，同时为投资者提供多样化的参与方式。\n此次备案符合生物科技行业常见的资本运作模式，这类企业通常需要通过阶段性融资支持临床研发及商业化进程。证券发行的具体条款、规模及时间表将视市场环境和公司战略需求最终确定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198027393","title":"X4制药全球4Ward三期慢性中性粒细胞减少症试验预计2026年第三季度完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1198027393","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198027393?lang=zh_cn&edition=full","pubTime":"2026-03-17 19:18","pubTimestamp":1773746322,"startTime":"0","endTime":"0","summary":"X4制药公司宣布，其针对慢性中性粒细胞减少症的全球4Ward三期临床试验进展顺利，目前正按计划推进，预计将于2026年第三季度完成患者招募工作。该试验旨在评估公司在研疗法对这类罕见血液疾病患者的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101292961","title":"X4制药公布2025年第四季度及全年财务业绩并通报公司进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1101292961","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101292961?lang=zh_cn&edition=full","pubTime":"2026-03-17 19:15","pubTimestamp":1773746114,"startTime":"0","endTime":"0","summary":"X4制药近日披露了2025年第四季度及全年度财务报告，同时就公司最新运营动态向市场作出说明。此次公告涵盖企业研发进展、战略布局及资金状况等关键信息，为投资者提供全面业务透视。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133987176","title":"X4制药：欧洲委员会将审核积极意见，最终批准决定预计于2026年第二季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1133987176","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133987176?lang=zh_cn&edition=full","pubTime":"2026-02-27 20:05","pubTimestamp":1772193920,"startTime":"0","endTime":"0","summary":"X4制药公司近日迎来关键进展——其获得的积极审评意见已正式提交至欧洲委员会进行最终审核。市场预期，这一重要监管流程的最终批准决定有望在2026年第二季度落地。此次进展标志着该公司在罕见病治疗领域的研发成果离欧洲市场准入更近一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614029055","title":"X4制药盘中异动 快速上涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614029055","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2614029055?lang=zh_cn&edition=full","pubTime":"2026-02-26 01:36","pubTimestamp":1772041001,"startTime":"0","endTime":"0","summary":"北京时间2026年02月26日01时36分，X4制药股票出现异动，股价大幅上涨5.01%。截至发稿，该股报3.56美元/股，成交量23.2526万股，换手率0.27%，振幅4.72%。机构评级方面，在所有3家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中，整体跌幅为0.38%。公司还有两种临床前候选药物X4P-003和X4P-002，它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226013641a4c81296&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226013641a4c81296&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518271968","title":"X4制药盘中异动 早盘急速跳水5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518271968","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518271968?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:36","pubTimestamp":1741617417,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时36分，X4制药股票出现波动，股价急速下跌5.09%。截至发稿，该股报0.334美元/股，成交量23.015万股，换手率0.13%，振幅5.57%。机构评级方面，在所有5家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中，整体涨幅为0.02%。它还拥有两个临床前候选药物X4P-003和X4P-002，它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223658a26a3dd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223658a26a3dd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517360507","title":"X4制药盘中异动 急速下挫5.00%报0.342美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517360507","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517360507?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:53","pubTimestamp":1741103595,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时53分，X4制药股票出现异动，股价大幅下跌5.00%。截至发稿，该股报0.342美元/股，成交量58.3037万股，换手率0.34%，振幅6.02%。机构评级方面，在所有5家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中，整体跌幅为0.21%。它还拥有两个临床前候选药物X4P-003和X4P-002，它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304235315989bc18b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304235315989bc18b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516632934","title":"X4制药盘中异动 早盘快速拉升5.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516632934","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516632934?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:34","pubTimestamp":1741012452,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时34分，X4制药股票出现异动，股价大幅上涨5.47%。截至发稿，该股报0.417美元/股，成交量11.791万股，换手率0.07%，振幅4.56%。X4制药股票所在的生物技术行业中，整体涨幅为0.38%。X4制药公司简介：X4 Pharmaceuticals Inc 是一家后期临床生物制药公司，致力于研究和开发治疗罕见疾病和治疗选择有限的疾病的新型疗法，重点关注由免疫系统功能障碍引起的疾病。它还拥有两个临床前候选药物X4P-003和X4P-002，它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223412abe63432&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223412abe63432&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514337651","title":"X4制药盘中异动 快速上涨6.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514337651","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514337651?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:18","pubTimestamp":1740755898,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日23时18分，X4制药股票出现异动，股价大幅上涨6.55%。截至发稿，该股报0.394美元/股，成交量57.3175万股，换手率0.34%，振幅7.93%。X4制药股票所在的生物技术行业中，整体涨幅为0.26%。X4制药公司简介：X4 Pharmaceuticals Inc 是一家后期临床生物制药公司，致力于研究和开发治疗罕见疾病和治疗选择有限的疾病的新型疗法，重点关注由免疫系统功能障碍引起的疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228231819abe0f638&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228231819abe0f638&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514363143","title":"X4制药盘中异动 大幅跳水5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514363143","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514363143?lang=zh_cn&edition=full","pubTime":"2025-02-28 02:27","pubTimestamp":1740680861,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日02时27分，X4制药股票出现异动，股价快速下挫5.04%。截至发稿，该股报0.386美元/股，成交量112.264万股，换手率0.66%，振幅7.84%。机构评级方面，在所有5家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中，整体涨幅为0.22%。它还拥有两个临床前候选药物X4P-003和X4P-002，它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228022741a256b15a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228022741a256b15a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514286864","title":"X4制药盘中异动 股价大跌5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514286864","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514286864?lang=zh_cn&edition=full","pubTime":"2025-02-27 04:00","pubTimestamp":1740600000,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日04时00分，X4制药股票出现异动，股价大幅下挫5.25%。截至发稿，该股报0.413美元/股，成交量97.6292万股，换手率0.57%，振幅7.93%。X4制药股票所在的生物技术行业中，整体跌幅为0.63%。X4制药公司简介：X4 Pharmaceuticals Inc 是一家后期临床生物制药公司，致力于研究和开发治疗罕见疾病和治疗选择有限的疾病的新型疗法，重点关注由免疫系统功能障碍引起的疾病。它还拥有两个临床前候选药物X4P-003和X4P-002，它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227040000abde3455&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227040000abde3455&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514821011","title":"X4制药盘中异动 早盘急速跳水5.24%报0.430美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514821011","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514821011?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:17","pubTimestamp":1740500257,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时17分，X4制药股票出现异动，股价急速跳水5.24%。截至发稿，该股报0.430美元/股，成交量34.3005万股，换手率0.20%，振幅6.13%。机构评级方面，在所有5家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中，整体涨幅为0.65%。它还拥有两个临床前候选药物X4P-003和X4P-002，它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226001737a2539f4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226001737a2539f4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513442720","title":"X4制药盘中异动 大幅下跌5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513442720","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513442720?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:55","pubTimestamp":1740408942,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时55分，X4制药股票出现波动，股价快速跳水5.14%。截至发稿，该股报0.443美元/股，成交量22.5575万股，换手率0.13%，振幅9.21%。机构评级方面，在所有5家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中，整体涨幅为0.12%。它还拥有两个临床前候选药物X4P-003和X4P-002，它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225542962e9ee5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225542962e9ee5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512165772","title":"X4制药盘中异动 早盘股价大涨6.78%报0.543美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512165772","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512165772?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:43","pubTimestamp":1739889784,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时43分，X4制药股票出现波动，股价大幅拉升6.78%。截至发稿，该股报0.543美元/股，成交量16.9739万股，换手率0.10%，振幅5.37%。最近的财报数据显示，该股实现营业收入560000.00美元，净利润-36.70百万美元，每股收益-0.18美元，毛利253000.00美元，市盈率-6.79倍。X4制药股票所在的生物技术行业中，整体涨幅为0.60%。它还拥有两个临床前候选药物X4P-003和X4P-002，它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218224304abd3b1da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218224304abd3b1da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511578121","title":"X4制药盘中异动 股价大涨5.20%报0.506美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511578121","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511578121?lang=zh_cn&edition=full","pubTime":"2025-02-14 01:16","pubTimestamp":1739467003,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日01时16分，X4制药股票出现波动，股价急速拉升5.20%。截至发稿，该股报0.506美元/股，成交量44.3566万股，换手率0.26%，振幅4.72%。最近的财报数据显示，该股实现营业收入560000.00美元，净利润-36.70百万美元，每股收益-0.18美元，毛利253000.00美元，市盈率-6.25倍。X4制药股票所在的生物技术行业中，整体涨幅为0.89%。它还拥有两个临床前候选药物X4P-003和X4P-002，它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021401164498844c68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021401164498844c68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510338706","title":"X4制药盘中异动 股价大跌5.77%报0.480美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510338706","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510338706?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:58","pubTimestamp":1739285903,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时58分，X4制药股票出现波动，股价急速跳水5.77%。截至发稿，该股报0.480美元/股，成交量30.8376万股，换手率0.18%，振幅6.26%。最近的财报数据显示，该股实现营业收入560000.00美元，净利润-36.70百万美元，每股收益-0.18美元，毛利253000.00美元，市盈率-6.15倍。X4制药股票所在的生物技术行业中，整体跌幅为1.34%。它还拥有两个临床前候选药物X4P-003和X4P-002，它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112258249881c263&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112258249881c263&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XFOR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510699068","title":"X4制药盘中异动 急速下挫5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510699068","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510699068?lang=zh_cn&edition=full","pubTime":"2025-02-10 23:22","pubTimestamp":1739200940,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日23时22分，X4制药股票出现异动，股价急速下挫5.16%。截至发稿，该股报0.502美元/股，成交量37.739万股，换手率0.22%，振幅5.04%。机构评级方面，在所有5家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中，整体跌幅为0.18%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502102322209880832a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502102322209880832a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509272764","title":"X4制药股价重挫18.82% 市值跌1607.42万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509272764","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509272764?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:31","pubTimestamp":1738852265,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日22时31分，X4制药股票出现波动，股价大幅下跌18.82%。截至发稿，该股报0.501美元/股，成交量178.147万股，换手率1.04%，振幅0.53%。机构评级方面，在所有5家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。X4制药股票所在的生物技术行业中，整体跌幅为0.12%。它还拥有两个临床前候选药物X4P-003和X4P-002，它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223105abc4d410&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223105abc4d410&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509580238","title":"X4制药盘中异动 早盘股价大涨5.25%报0.627美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509580238","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509580238?lang=zh_cn&edition=full","pubTime":"2025-02-05 23:24","pubTimestamp":1738769059,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日23时24分，X4制药股票出现异动，股价大幅拉升5.25%。截至发稿，该股报0.627美元/股，成交量41.4124万股，换手率0.24%，振幅7.60%。最近的财报数据显示，该股实现营业收入560000.00美元，净利润-36.70百万美元，每股收益-0.18美元，毛利253000.00美元，市盈率-7.82倍。X4制药股票所在的生物技术行业中，整体涨幅为1.35%。它还拥有两个临床前候选药物X4P-003和X4P-002，它们是具有不同性质的CXCR4拮抗剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205232419a23a8775&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205232419a23a8775&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XFOR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.x4pharma.com","stockEarnings":[{"period":"1week","weight":0.0024},{"period":"1month","weight":0.0584},{"period":"3month","weight":0.0072},{"period":"6month","weight":0.2122},{"period":"1year","weight":-0.0895},{"period":"ytd","weight":0.0425}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0152},{"period":"6month","weight":0.1168},{"period":"1year","weight":0.1874},{"period":"ytd","weight":0.1234}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"X4 Pharmaceuticals, Inc.于2010年8月2日根据特拉华州法律注册成立。该公司是一家晚期临床阶段的生物制药公司，发现和开发用于治疗罕见疾病和治疗选择有限的疾病的新疗法，重点关注免疫系统功能障碍导致的疾病。该公司的主要临床候选药物是mavorixafor，这是一种趋化因子受体CXCR4的小分子选择性拮抗剂，正在开发为一种口服、每日一次的疗法。由于mavorixafor能够增加成熟、功能性白细胞进入血液的动员，该公司认为mavorixafor有可能在多种慢性中性粒细胞减少症中提供治疗益处，包括WHIM（疣、低丙种球蛋白血症、感染和骨髓松弛症）综合征，这是一种罕见的原发性免疫缺陷。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.010739},{"month":2,"riseRate":0.555556,"avgChangeRate":0.007538},{"month":3,"riseRate":0.555556,"avgChangeRate":0.084933},{"month":4,"riseRate":0.222222,"avgChangeRate":-0.024796},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.029707},{"month":6,"riseRate":0.222222,"avgChangeRate":-0.22977},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.05185},{"month":8,"riseRate":0.444444,"avgChangeRate":0.072007},{"month":9,"riseRate":0.25,"avgChangeRate":-0.001382},{"month":10,"riseRate":0.25,"avgChangeRate":-0.084011},{"month":11,"riseRate":0.25,"avgChangeRate":0.161316},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.049964}],"exchange":"NASDAQ","name":"X4制药","nameEN":"X4 Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"X4制药(XFOR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供X4制药(XFOR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"X4制药,XFOR,X4制药股票,X4制药股票老虎,X4制药股票老虎国际,X4制药行情,X4制药股票行情,X4制药股价,X4制药股市,X4制药股票价格,X4制药股票交易,X4制药股票购买,X4制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"X4制药(XFOR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供X4制药(XFOR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}